HIV-1 Infection
Conditions
Brief summary
The main goal of this study was to see if a drug called telmisartan would decrease fibrosis (scarring) and inflammation (irritation) in people who are infected with HIV and doing well on their HIV medications. The study was also done to see what effects telmisartan has on other signs of disease and inflammation in the body, and to see whether people who have HIV can take telmisartan safely and without side effects that make them want to stop the drug. Telmisartan is FDA-approved for treating high blood pressure and decreasing the chance of heart attacks and strokes in people over the age of 55 years of age who are at high risk for these events.
Detailed description
This was a multicenter, randomized, open label, phase IIb, two-arm study to evaluate the effects of telmisartan on fibrotic and inflammatory contributors to end-organ disease in HIV-infected subjects well controlled on antiretroviral therapy (ART). Participants were randomized 2:1 to the telmisartan and control arms. The participants on telmisartan took 40 mg telmisartan daily during weeks 0-4 followed by telmisartan 80 mg daily during weeks 5-48. The participants in the control arm did not take any study medication, but did undergo all evaluations. All participants were followed for 48 weeks after randomization. The study clinic visits included Step 1 entry, Step 2 entry, and weeks 4, 12, 24, 36, 48. Biopsies for the primary outcomes were collected at Step 1 entry and Week 48. The evaluations of safety (clinical assessment for signs and symptoms, diagnoses, laboratory tests) were done at Step 2 entry and weeks 4, 12, 24, 36, 48. The co-primary objectives assessed the effects of telmisartan for 48weeks on lymph node and adipose tissue collagen I deposition. Currently, the results are entered for the primary outcome measures only. The results on the secondary outcomes will be posted when they become available.
Interventions
DRUGTelmisartan
Participants received Telmisartan 40 mg daily during weeks 0-4 followed by telmisartan 80 mg daily during weeks 5-48.
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Step 1 Inclusion Criteria: * HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to Step 1 entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, or plasma HIV-1 RNA viral load \>2000 copies/mL on two occasions. * On antiretroviral therapy (ART) continuously for ≥48 weeks prior to Step 1 entry. * Documentation of HIV-1 RNA \<50 copies/mL at screening, performed by any US laboratory that has a CLIA certification or its equivalent. * At least one HIV-1 RNA level \<200 copies/mL in the 48 weeks prior to Step 1 entry (not including the screening). * No change in ART regimen in the 12 weeks prior to Step 1 entry (except as noted below). NOTE: Modifications of ART dosing during the 12 weeks prior to Step 1 entry are permitted. In addition, the change in formulation (eg, from standard formulation to fixed dose combination or single tablet regimen) is allowed within 12 weeks of Step 1 entry. A within-class single drug substitution (eg, switch from nevirapine to efavirenz or from atazanavir to darunavir) is allowed within 12 weeks of Step 1 entry, with the exception of a switch from any other NRTI to abacavir. No other changes in ART in the 12 weeks prior to Step 1 entry are permitted. * No active plan to change ART for the 48-week study duration. * Body mass index (BMI) 20-35 kg/m\^2. * For females of reproductive potential, negative serum or urine pregnancy test within 3 days prior to Step 1 entry. * Ability and willingness of subject or legal guardian/representative to provide informed consent. * Willingness to undergo the Step 1 entry and week 48 lymphoid and adipose tissue biopsies. Step 2 Inclusion Criteria: * Entry lymphoid tissue and adipose tissue specimen for assay of the primary endpoint has been obtained. (Prior to Letter of Amendment #2, 11/19/14) * (Letter of Amendment #2, 11/19/14) Entry lymphoid tissue and adipose tissue specimens for assay of the primary endpoint have been obtained, entered into the ACTG's Laboratory Data Management System (LDMS), and confirmed by the protocol team as adequate for endpoint determination. NOTE: If the lymph node specimen is determined by the protocol team to be inadequate for endpoint determination despite the interventions summarized in LOA #2, the participant will be permitted to enroll if adequate adipose tissue is obtained. However, as change in lymph node fibrosis remains one of the primary endpoints of this study, it is critical that every effort be made to obtain an adequate sample while still trying to minimize complication rates. * Willingness to undergo the week 48 lymphoid and adipose tissue biopsies. (Prior to Letter of Amendment #2, 11/19/14) * (Letter of Amendment #2, 11/19/14) Willingness to undergo the week 48 lymphoid and adipose tissue biopsies. NOTE: A week 48 lymph node biopsy is not required if the Step 1 lymph node specimen was deemed inadequate as noted in 4.3.1. Week 48 adipose tissue biopsies will still be required for these participants. Step 1
Exclusion criteria
* More than one HIV-1 RNA \>200 copies/mL in the 48 weeks prior to Step 1 entry. * One HIV-1 RNA 200-500 copies/mL in the 24 weeks prior to Step 1 entry that is not immediately preceded and followed by HIV-1 RNA \<50 copies/mL. NOTE: The preceding viral load \<50 copies/mL may be \>24 weeks prior to Step 1 entry. * Confirmed systolic blood pressure \>160 mmHg or \<100 mmHg or diastolic blood pressure \>100 mmHg. * Known untreated renal artery stenosis. * Known cirrhosis or severe liver disease (eg, ascites, encephalopathy, history of variceal bleeding). NOTE: Potential subjects with chronic hepatitis B or C virus infection with no known cirrhosis or severe liver disease may participate in the study, provided there are no plans to start therapy for hepatitis C infection during the 48-week study duration. * Unstable coronary artery disease/angina or decompensated congestive heart failure. * Either breastfeeding or pregnant within 24 weeks prior to Step 1 entry. * Use of thiazolidinediones or any angiotensin receptor blocker (ARB) or angiotensin converting enzyme inhibitor (ACEi) in the 24 weeks prior to Step 1 entry. If the subject took either of these classes of medications for less than 2 weeks in the 24 weeks prior to Step 1 entry, the subject may enroll if 30 days have passed since the last dose. If the subject is diabetic and/or has a calculated glomerular filtration rate (GFR) \<60mL/min, aliskiren-containing medications are also prohibited. * History of intolerance, other than cough, to any ARB or ACEi. * Use of anticoagulants other than aspirin 81 mg or 325 mg daily. NOTE: If the subject is on aspirin 81 mg or 325 mg daily and is willing/able to stop therapy for 7 days prior to the biopsy procedures, the subject may enroll. * Any known bleeding disorder or coagulopathy. * Projected need for daily potassium supplementation for ≥2 weeks during the study period. * The following laboratory values obtained within 30 days prior to Step 1 entry by any US laboratory that has a CLIA certification or its equivalent: * Absolute neutrophil count (ANC) ≤750 cells/mm\^3 * Hemoglobin ≤10 g/dL * Platelet count ≤75,000/mm\^3 * Calculated creatinine clearance (CrCl) \<50 mL/min, as estimated by the Cockcroft-Gault equation * Aspartate aminotransferase (AST) (SGOT) \>/=3x ULN (upper limit of normal) * Alanine aminotransferase (ALT) (SGPT) \>/=3x ULN * Partial thromboplastin time (PTT) \>1.2x ULN * Prothrombin time (PT) \>1.2x ULN * Heritable connective tissue disorders (eg Ehlers-Danlos syndrome, osteogenesis imperfecta, Stickler syndrome, Marfan's syndrome). NOTE: Subjects with acquired/autoimmune chronic inflammatory diseases/connective tissue disorders who are clinically stable (in the opinion of the site investigator) and not on a prohibited medication may enroll with approval of the A5317 study chairs. * Serious illness requiring systemic treatment and/or hospitalization until subject either completes therapy or is clinically stable on therapy, in the opinion of the site investigator, for at least 7 days prior to Step 1 entry. * Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. * Any condition that, in the opinion of the site investigator, would compromise the subject's ability to participate in the study. Step 2
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Percent Collagen I Deposition on Lymph Node Pathology From Baseline to Week 48 | baseline and week 48 | Percent collagen I deposition is defined as the average % collagen stained in multiple uniform sized high magnification images in each sample. Change was absolute change defined as the Week 48 value minus the baseline value. |
| Change in Percent Collagen I Deposition on Subcutaneous Abdominal Adipose Tissue Pathology From Baseline to Week 48 | baseline and week 48 | Percent collagen I deposition defined as percentage of fibrotic/collagen area to total area. Change was absolute change defined as the Week 48 value minus the baseline value. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Percent Fibronectin Deposition on Subcutaneous Abdominal Adipose Tissue Pathology From Baseline to Week 48 | baseline and week 48 | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in Percent Collagen VI Deposition on Subcutaneous Abdominal Adipose Tissue Pathology From Baseline to Week 48 | baseline and week 48 | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Highest Grade Non-biopsy-related Adverse Event | after baseline to week 48 | Safety was summarized as the highest grade non-biopsy-related sign/symptom, laboratory event, or diagnosis per participant. Grading (Grade 0: normal, Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life-threatening) was done by site clinicians using DAIDS AE Grading table. NOTE: As adipose tissue and lymph node biopsies are generally considered to be minimal risk procedures, biopsy safety profile were not formally be evaluated as an endpoint in this protocol. |
| Change in IL-6 From Baseline to Week 4 | baseline and week 4 | Absolute change was calculated as the value at week 4 minus the value at baseline. |
| Change in IL-6 From Baseline to Week 24 | baseline and week 24 | Absolute change was calculated as the value at week 24 minus the value at baseline. |
| Change in IL-6 From Baseline to Week 48 | baseline and week 48 | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in IL-7 From Baseline to Week 4 | baseline and week 4 | Absolute change was calculated as the value at week 4 minus the value at baseline. |
| Change in IL-7 From Baseline to Week 24 | baseline and week 24 | Absolute change was calculated as the value at week 24 minus the value at baseline. |
| Change in IL-7 From Baseline to Week 48 | baseline and week 48 | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in Adiponectin From Baseline to Week 4 | baseline and week 4 | Absolute change was calculated as the value at week 4 minus the value at baseline. |
| Change in Adiponectin From Baseline to Week 24 | baseline and week 24 | Absolute change was calculated as the value at week 24 minus the value at baseline. |
| Change in Adiponectin From Baseline to Week 48 | baseline and week 48 | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in Collagen I C-terminal Pro-peptide (CICP) From Baseline to Week 4 | baseline and week 4 | Absolute change was calculated as the value at week 4 minus the value at baseline. |
| Change in Collagen I C-terminal Pro-peptide (CICP) From Baseline to Week 24 | baseline and week 24 | Absolute change was calculated as the value at week 24 minus the value at baseline. |
| Change in Collagen I C-terminal Pro-peptide (CICP) From Baseline to Week 48 | baseline and week 48 | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in Hyaluronic Acid From Baseline to Week 4 | baseline and week 4 | Absolute change was calculated as the value at week 4 minus the value at baseline. |
| Change in Hyaluronic Acid From Baseline to Week 24 | baseline and week 24 | Absolute change was calculated as the value at week 24 minus the value at baseline. |
| Change in Hyaluronic Acid From Baseline to Week 48 | baseline and week 48 | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in sCD14 From Baseline to Week 24 | baseline and week 24 | Absolute change was calculated as the value at week 24 minus the value at baseline. |
| Change in sCD14 From Baseline to Week 48 | baseline and week 48 | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in sCD163 From Baseline to Week 4 | baseline and week 4 | Absolute change was calculated as the value at week 4 minus the value at baseline. |
| Change in sCD163 From Baseline to Week 24 | baseline and week 24 | Absolute change was calculated as the value at week 24 minus the value at baseline. |
| Change in Fasting LDL Cholesterol From Baseline to Week 48 | baseline and week 48 | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in sCD163 From Baseline to Week 48 | baseline and week 48 | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in TGF-β1 From Baseline to Week 4 | baseline and week 4 | Absolute change was calculated as the value at week 4 minus the value at baseline. |
| Change in TGF-β1 From Baseline to Week 24 | baseline and week 24 | Absolute change was calculated as the value at week 24 minus the value at baseline. |
| Change in TGF-β1 From Baseline to Week 48 | baseline and week 48 | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in TGF-β2 From Baseline to Week 4 | baseline and week 4 | Absolute change was calculated as the value at week 4 minus the value at baseline. |
| Change in TGF-β2 From Baseline to Week 24 | baseline and week 24 | Absolute change was calculated as the value at week 24 minus the value at baseline. |
| Change in TGF-β2 From Baseline to Week 48 | baseline and week 48 | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in TGF-β3 From Baseline to Week 4 | baseline and week 4 | Absolute change was calculated as the value at week 4 minus the value at baseline. |
| Change in TGF-β3 From Baseline to Week 24 | baseline and week 24 | Absolute change was calculated as the value at week 24 minus the value at baseline. |
| Change in TGF-β3 From Baseline to Week 48 | baseline and week 48 | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in Circulating CD4+ T Cell Count From Baseline to Week 12 | baseline and week 12 | Absolute change was calculated as the value at week 12 minus the value at baseline. |
| Change in Circulating CD4+ T Cell Count From Baseline to Week 24 | baseline and week 24 | Absolute change was calculated as the value at week 24 minus the value at baseline. |
| Change in Circulating CD4+ T Cell Count From Baseline to Week 48 | baseline and week 48 | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in Circulating CD8+ T Cell Count From Baseline to Week 12 | baseline and week 12 | Absolute change was calculated as the value at week 12 minus the value at baseline. |
| Change in Circulating CD8+ T Cell Count From Baseline to Week 24 | baseline and week 24 | Absolute change was calculated as the value at week 24 minus the value at baseline. |
| Change in Circulating CD8+ T Cell Count From Baseline to Week 48 | baseline and week 48 | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in Fasting Glucose From Baseline to Week 48 | baseline and week 48 | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in Fasting HDL Cholesterol From Baseline to Week 48 | baseline and week 48 | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in Fasting Insulin From Baseline to Week 48 | baseline and week 48 | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in Fasting Total Cholesterol From Baseline to Week 48 | baseline and week 48 | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in Fasting Triglycerides From Baseline to Week 48 | baseline and week 48 | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in HOMA-IR From Baseline to Week 48 | baseline and week 48 | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Prevalence of Metabolic Syndrome at Week 24. | Week 24 | Components of the metabolic syndrome will be defined according to the 2004 updated National Cholesterol Education Program Adult Treatment Panel III \[NCEP ATP III\] criteria) as the presence of any 3 of the following: Waist: \>40 (101.6 cm) in men, \>35 (88.9 cm) in women with the exception of Asian-Americans: \>35 (88.9 cm) in men, 31 (78.7 cm) in women; Fasting HDL-C \<40 mg/dL in men, \<50 mg/dL in women; Fasting TG ≥150 mg/dL; Diastolic blood pressure ≥85 mmHg or systolic blood pressure ≥130 mmHg; Fasting plasma glucose ≥100 mg/dL. NOTE: This definition of metabolic syndrome may be subject to change in accordance with current guidelines at the time of the final analysis. It will be defined in the Final Statistical Analysis Plan prior to data review for final analysis. |
| Presence of Metabolic Syndrome at Week 48. | Week 48 | Components of the metabolic syndrome were defined according to the 2004 updated National Cholesterol Education Program Adult Treatment Panel III \[NCEP ATP III\] criteria) as the presence of any 3 of the following: Waist: \>40 (101.6 cm) in men, \>35 (88.9 cm) in women with the exception of Asian-Americans: \>35 (88.9 cm) in men, 31 (78.7 cm) in women; Fasting HDL-C \<40 mg/dL in men, \<50 mg/dL in women; Fasting TG ≥150 mg/dL; Diastolic blood pressure ≥85 mmHg or systolic blood pressure ≥130 mmHg; Fasting plasma glucose ≥100 mg/dL. |
| Change in Waist Circumference From Baseline to Week 24 | baseline and week 24 | Absolute change was calculated as the value at week 24 minus the value at baseline. |
| Change in Waist Circumference From Baseline to Week 48 | baseline and week 48 | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in Waist-to-hip Ratio From Baseline to Week 24 | baseline and week 24 | Absolute change was calculated as the value at week 24 minus the value at baseline. |
| Change in Waist-to-hip Ratio From Baseline to Week 48 | baseline and week 48 | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in Expression of CD38+HLA-DR+ on CD4+ From Baseline to Week 24 | 24 weeks | Absolute change was calculated as the value at week 24 minus the value at baseline. |
| Change in Expression of CD38+HLA-DR+ on CD8+ From Baseline to Week 24 | 24 weeks | Absolute change was calculated as the value at week 24 minus the value at baseline. |
| Change in Expression of CD38+HLA-DR+ on CD4+ From Baseline to Week 48 | 48 weeks | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in Expression of CD38+HLA-DR+ on CD8+ From Baseline to Week 48 | 48 weeks | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in sCD14 From Baseline to Week 4 | baseline and week 4 | Absolute change was calculated as the value at week 4 minus the value at baseline. |
| Change in Expression of CD4+ in Lymphoid Tissue From Baseline to Week 48. | 48 weeks | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in Expression of CD8+ in Lymphoid Tissue From Baseline to Week 48. | 48 weeks | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in Expression of CD163+ in Lymphoid Tissue From Baseline to Week 48. | 48 weeks | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in Expression of CD68+ in Lymphoid Tissue From Baseline to Week 48. | 48 weeks | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in Expression of CD38+HLA-DR+ on CD4+ in Lymphoid Tissue From Baseline to Week 48. | 48 weeks | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in Expression of CD38+HLA-DR+ on CD8+ in Lymphoid Tissue From Baseline to Week 48. | 48 weeks | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in Expression of CD163+ in Adipose Tissue From Baseline to Week 48 | 48 weeks | Absolute change was calculated as the value at week 48 minus the value at baseline. |
| Change in Percent Fibronectin Deposition on Lymph Node Pathology From Baseline to Week 48 | baseline and week 48 | Absolute change was calculated as the value at week 48 minus the value at baseline. |
Countries
Puerto Rico, United States
Participant flow
Recruitment details
58 participants enrolled to Step 1 between January 6, 2014 and April 13, 2015. Step 1 was a run-in period to ensure successful pre-randomization biopsies were obtained. 44 participants did have successful Step 1 biopsy and were randomized to Step 2 between January 13, 2014 and April 22, 2015.
Pre-assignment details
All participants enrolled to Step 1. Participants with successful Step 1 biopsies and eligible for Step 2 were randomized to the two study arms using a 2:1 allocation ratio with permuted blocks of size 3 and without institutional balancing. There was no stratification.
Participants by arm
| Arm | Count |
|---|---|
| Arm A: Telmisartan Participants received Telmisartan 40 mg daily during weeks 0-4 followed by telmisartan 80 mg daily during weeks 5-48.
Telmisartan | 29 |
| Arm B: No Study Drug Participants received no study drug and were followed week 0-48 evaluation schedule.
Control | 15 |
| Total | 44 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Lost to Follow-up | 1 | 0 |
| Overall Study | Withdrawal by Subject | 1 | 1 |
Baseline characteristics
| Characteristic | Arm A: Telmisartan | Arm B: No Study Drug | Total |
|---|---|---|---|
| Adipose Tissue Collagen I Deposition | 1.51 percent area stain positive | 2.83 percent area stain positive | 2.11 percent area stain positive |
| Age, Continuous | 47 years | 50 years | 48 years |
| Age, Customized 18-29 years | 0 Participants | 2 Participants | 2 Participants |
| Age, Customized 30-39 years | 6 Participants | 2 Participants | 8 Participants |
| Age, Customized 40-49 years | 12 Participants | 3 Participants | 15 Participants |
| Age, Customized 50-59 years | 11 Participants | 6 Participants | 17 Participants |
| Age, Customized 60-69 years | 0 Participants | 2 Participants | 2 Participants |
| BMI | 25.4 kg/m^2 | 23.7 kg/m^2 | 25.0 kg/m^2 |
| CD4+ | 604 cells/mm^3 | 556 cells/mm^3 | 588 cells/mm^3 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 7 Participants | 1 Participants | 8 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 22 Participants | 14 Participants | 36 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| HIV-1 RNA >= 200 copies/ml | 2 Participants | 1 Participants | 3 Participants |
| HIV-1 RNA 40 - <200 copies/ml | 3 Participants | 3 Participants | 6 Participants |
| HIV-1 RNA <40 copies/ml | 24 Participants | 11 Participants | 35 Participants |
| IV drug history No History | 25 Participants | 13 Participants | 38 Participants |
| IV drug history Previous History | 4 Participants | 2 Participants | 6 Participants |
| Lymphoid Tissue Collagen I Deposition | 15.3 percent area stain positive | 12.6 percent area stain positive | 13.9 percent area stain positive |
| Race/Ethnicity, Customized Black Non-Hispanic | 5 Participants | 8 Participants | 13 Participants |
| Race/Ethnicity, Customized Hispanic (Regardless of Race) | 7 Participants | 1 Participants | 8 Participants |
| Race/Ethnicity, Customized More than one race | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized White Non-Hispanic | 16 Participants | 6 Participants | 22 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 6 Participants | 8 Participants | 14 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 22 Participants | 7 Participants | 29 Participants |
| Sex: Female, Male Female | 2 Participants | 1 Participants | 3 Participants |
| Sex: Female, Male Male | 27 Participants | 14 Participants | 41 Participants |
| Waist circumference | 92 cm | 86 cm | 88 cm |
| Waist-to-hip ratio | 0.94 ratio | 0.91 ratio | 0.93 ratio |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 29 | 0 / 15 |
| other Total, other adverse events | 24 / 29 | 10 / 15 |
| serious Total, serious adverse events | 3 / 29 | 1 / 15 |
Outcome results
Primary
Change in Percent Collagen I Deposition on Lymph Node Pathology From Baseline to Week 48
Percent collagen I deposition is defined as the average % collagen stained in multiple uniform sized high magnification images in each sample. Change was absolute change defined as the Week 48 value minus the baseline value.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing lymphoid tissue collagen I deposition.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Percent Collagen I Deposition on Lymph Node Pathology From Baseline to Week 48 | -2.44 percent area stain positive |
| Arm B: No Study Drug | Change in Percent Collagen I Deposition on Lymph Node Pathology From Baseline to Week 48 | -6.08 percent area stain positive |
Comparison: Null hypothesis: theta = 0.50p-value: 0.9795% CI: [0.26, 0.73]Theta statistic; DeLong & Clarke-Pearson
Primary
Change in Percent Collagen I Deposition on Subcutaneous Abdominal Adipose Tissue Pathology From Baseline to Week 48
Percent collagen I deposition defined as percentage of fibrotic/collagen area to total area. Change was absolute change defined as the Week 48 value minus the baseline value.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing subcutaneous abdominal adipose tissue collagen I deposition.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Percent Collagen I Deposition on Subcutaneous Abdominal Adipose Tissue Pathology From Baseline to Week 48 | -1.43 percent area stain positive |
| Arm B: No Study Drug | Change in Percent Collagen I Deposition on Subcutaneous Abdominal Adipose Tissue Pathology From Baseline to Week 48 | 0.36 percent area stain positive |
Comparison: Null hypothesis: theta = 0.50p-value: 0.6195% CI: [0.31, 0.83]Theta statistic; DeLong & Clarke-Pearson
Secondary
Change in Adiponectin From Baseline to Week 24
Absolute change was calculated as the value at week 24 minus the value at baseline.
Time frame: baseline and week 24
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing adiponectin.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Adiponectin From Baseline to Week 24 | -582 ng/ml |
| Arm B: No Study Drug | Change in Adiponectin From Baseline to Week 24 | 1222.60 ng/ml |
Secondary
Change in Adiponectin From Baseline to Week 4
Absolute change was calculated as the value at week 4 minus the value at baseline.
Time frame: baseline and week 4
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing adiponectin.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Adiponectin From Baseline to Week 4 | 177.20 ng/ml |
| Arm B: No Study Drug | Change in Adiponectin From Baseline to Week 4 | 161.00 ng/ml |
Secondary
Change in Adiponectin From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing adiponectin.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Adiponectin From Baseline to Week 48 | -138.70 ng/ml |
| Arm B: No Study Drug | Change in Adiponectin From Baseline to Week 48 | 113.80 ng/ml |
Secondary
Change in Circulating CD4+ T Cell Count From Baseline to Week 12
Absolute change was calculated as the value at week 12 minus the value at baseline.
Time frame: baseline and week 12
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing CD4+ count.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Circulating CD4+ T Cell Count From Baseline to Week 12 | -17.50 cells/mm^3 |
| Arm B: No Study Drug | Change in Circulating CD4+ T Cell Count From Baseline to Week 12 | 59.50 cells/mm^3 |
Secondary
Change in Circulating CD4+ T Cell Count From Baseline to Week 24
Absolute change was calculated as the value at week 24 minus the value at baseline.
Time frame: baseline and week 24
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing CD4+ count.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Circulating CD4+ T Cell Count From Baseline to Week 24 | 13 cells/mm^3 |
| Arm B: No Study Drug | Change in Circulating CD4+ T Cell Count From Baseline to Week 24 | 61.5 cells/mm^3 |
Secondary
Change in Circulating CD4+ T Cell Count From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing CD4+ count.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Circulating CD4+ T Cell Count From Baseline to Week 48 | 9 cells/mm^3 |
| Arm B: No Study Drug | Change in Circulating CD4+ T Cell Count From Baseline to Week 48 | 97 cells/mm^3 |
Secondary
Change in Circulating CD8+ T Cell Count From Baseline to Week 12
Absolute change was calculated as the value at week 12 minus the value at baseline.
Time frame: baseline and week 12
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing CD8+ count.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Circulating CD8+ T Cell Count From Baseline to Week 12 | -33.5 cells/mm^3 |
| Arm B: No Study Drug | Change in Circulating CD8+ T Cell Count From Baseline to Week 12 | 83 cells/mm^3 |
Secondary
Change in Circulating CD8+ T Cell Count From Baseline to Week 24
Absolute change was calculated as the value at week 24 minus the value at baseline.
Time frame: baseline and week 24
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing CD8+ count.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Circulating CD8+ T Cell Count From Baseline to Week 24 | -3.5 cells/mm^3 |
| Arm B: No Study Drug | Change in Circulating CD8+ T Cell Count From Baseline to Week 24 | 80.5 cells/mm^3 |
Secondary
Change in Circulating CD8+ T Cell Count From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing CD8+ count.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Circulating CD8+ T Cell Count From Baseline to Week 48 | 10 cells/mm^3 |
| Arm B: No Study Drug | Change in Circulating CD8+ T Cell Count From Baseline to Week 48 | 97 cells/mm^3 |
Secondary
Change in Collagen I C-terminal Pro-peptide (CICP) From Baseline to Week 24
Absolute change was calculated as the value at week 24 minus the value at baseline.
Time frame: baseline and week 24
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing CICP.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Collagen I C-terminal Pro-peptide (CICP) From Baseline to Week 24 | -13.78 ng/ml |
| Arm B: No Study Drug | Change in Collagen I C-terminal Pro-peptide (CICP) From Baseline to Week 24 | -1.17 ng/ml |
Secondary
Change in Collagen I C-terminal Pro-peptide (CICP) From Baseline to Week 4
Absolute change was calculated as the value at week 4 minus the value at baseline.
Time frame: baseline and week 4
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing CICP.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Collagen I C-terminal Pro-peptide (CICP) From Baseline to Week 4 | -2.14 ng/ml |
| Arm B: No Study Drug | Change in Collagen I C-terminal Pro-peptide (CICP) From Baseline to Week 4 | -9.10 ng/ml |
Secondary
Change in Collagen I C-terminal Pro-peptide (CICP) From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing CICP.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Collagen I C-terminal Pro-peptide (CICP) From Baseline to Week 48 | -10.76 ng/ml |
| Arm B: No Study Drug | Change in Collagen I C-terminal Pro-peptide (CICP) From Baseline to Week 48 | -6.10 ng/ml |
Secondary
Change in Expression of CD163+ in Adipose Tissue From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: 48 weeks
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing CD163+ adipose tissue data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Expression of CD163+ in Adipose Tissue From Baseline to Week 48 | -0.19 Percent of CD163+ adipose tissue cells |
| Arm B: No Study Drug | Change in Expression of CD163+ in Adipose Tissue From Baseline to Week 48 | 0.87 Percent of CD163+ adipose tissue cells |
Secondary
Change in Expression of CD163+ in Lymphoid Tissue From Baseline to Week 48.
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: 48 weeks
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing CD163+ lymphoid tissue data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Expression of CD163+ in Lymphoid Tissue From Baseline to Week 48. | -0.13 Percent of CD163+ lymphoid tissue cells |
| Arm B: No Study Drug | Change in Expression of CD163+ in Lymphoid Tissue From Baseline to Week 48. | 0.15 Percent of CD163+ lymphoid tissue cells |
Secondary
Change in Expression of CD38+HLA-DR+ on CD4+ From Baseline to Week 24
Absolute change was calculated as the value at week 24 minus the value at baseline.
Time frame: 24 weeks
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing CD4+CD38+HLA-DR+ data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Expression of CD38+HLA-DR+ on CD4+ From Baseline to Week 24 | 0.20 Percent of CD4+ expressing CD38+HLA-DR+ |
| Arm B: No Study Drug | Change in Expression of CD38+HLA-DR+ on CD4+ From Baseline to Week 24 | -1.35 Percent of CD4+ expressing CD38+HLA-DR+ |
Secondary
Change in Expression of CD38+HLA-DR+ on CD4+ From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: 48 weeks
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing CD4+CD38+HLA-DR+ data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Expression of CD38+HLA-DR+ on CD4+ From Baseline to Week 48 | -0.30 Percent of CD4+ expressing CD38+HLA-DR+ |
| Arm B: No Study Drug | Change in Expression of CD38+HLA-DR+ on CD4+ From Baseline to Week 48 | -0.60 Percent of CD4+ expressing CD38+HLA-DR+ |
Secondary
Change in Expression of CD38+HLA-DR+ on CD4+ in Lymphoid Tissue From Baseline to Week 48.
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: 48 weeks
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing CD38+HLA-DR+ on CD4+ lymphoid tissue data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Expression of CD38+HLA-DR+ on CD4+ in Lymphoid Tissue From Baseline to Week 48. | -0.33 Percent of CD38+HLA-DR+ on CD4+ cells |
| Arm B: No Study Drug | Change in Expression of CD38+HLA-DR+ on CD4+ in Lymphoid Tissue From Baseline to Week 48. | 0.06 Percent of CD38+HLA-DR+ on CD4+ cells |
Secondary
Change in Expression of CD38+HLA-DR+ on CD8+ From Baseline to Week 24
Absolute change was calculated as the value at week 24 minus the value at baseline.
Time frame: 24 weeks
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing CD8+CD38+HLA-DR+ data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Expression of CD38+HLA-DR+ on CD8+ From Baseline to Week 24 | 0.60 Percent of CD8+ expressing CD38+HLA-DR+ |
| Arm B: No Study Drug | Change in Expression of CD38+HLA-DR+ on CD8+ From Baseline to Week 24 | -0.95 Percent of CD8+ expressing CD38+HLA-DR+ |
Secondary
Change in Expression of CD38+HLA-DR+ on CD8+ From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: 48 weeks
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing CD8+CD38+HLA-DR+ data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Expression of CD38+HLA-DR+ on CD8+ From Baseline to Week 48 | -0.40 Percent of CD8+ expressing CD38+HLA-DR+ |
| Arm B: No Study Drug | Change in Expression of CD38+HLA-DR+ on CD8+ From Baseline to Week 48 | -0.20 Percent of CD8+ expressing CD38+HLA-DR+ |
Secondary
Change in Expression of CD38+HLA-DR+ on CD8+ in Lymphoid Tissue From Baseline to Week 48.
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: 48 weeks
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing CD38+HLA-DR+ on CD8+ lymphoid tissue data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Expression of CD38+HLA-DR+ on CD8+ in Lymphoid Tissue From Baseline to Week 48. | 0.13 Percent of CD38+HLA-DR+ on CD8+ cells |
| Arm B: No Study Drug | Change in Expression of CD38+HLA-DR+ on CD8+ in Lymphoid Tissue From Baseline to Week 48. | -0.22 Percent of CD38+HLA-DR+ on CD8+ cells |
Secondary
Change in Expression of CD4+ in Lymphoid Tissue From Baseline to Week 48.
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: 48 weeks
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing CD4+ lymphoid tissue data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Expression of CD4+ in Lymphoid Tissue From Baseline to Week 48. | 1 Percent of CD4+ lymphoid tissue cells |
| Arm B: No Study Drug | Change in Expression of CD4+ in Lymphoid Tissue From Baseline to Week 48. | -7.8 Percent of CD4+ lymphoid tissue cells |
Secondary
Change in Expression of CD68+ in Lymphoid Tissue From Baseline to Week 48.
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: 48 weeks
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing CD68+ lymphoid tissue data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Expression of CD68+ in Lymphoid Tissue From Baseline to Week 48. | -0.02 Percent of CD68+ lymphoid tissue cells |
| Arm B: No Study Drug | Change in Expression of CD68+ in Lymphoid Tissue From Baseline to Week 48. | 0.08 Percent of CD68+ lymphoid tissue cells |
Secondary
Change in Expression of CD8+ in Lymphoid Tissue From Baseline to Week 48.
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: 48 weeks
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing CD8+ lymphoid tissue data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Expression of CD8+ in Lymphoid Tissue From Baseline to Week 48. | -1.19 Percent of CD8+ lymphoid tissue cells |
| Arm B: No Study Drug | Change in Expression of CD8+ in Lymphoid Tissue From Baseline to Week 48. | 3.9 Percent of CD8+ lymphoid tissue cells |
Secondary
Change in Fasting Glucose From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing fasting glucose.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Fasting Glucose From Baseline to Week 48 | 4 mg/dl |
| Arm B: No Study Drug | Change in Fasting Glucose From Baseline to Week 48 | 2 mg/dl |
Secondary
Change in Fasting HDL Cholesterol From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing fasting HDL cholesterol.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Fasting HDL Cholesterol From Baseline to Week 48 | -1 mg/dl |
| Arm B: No Study Drug | Change in Fasting HDL Cholesterol From Baseline to Week 48 | -4 mg/dl |
Secondary
Change in Fasting Insulin From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing fasting insulin.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Fasting Insulin From Baseline to Week 48 | 3 uIU/ml |
| Arm B: No Study Drug | Change in Fasting Insulin From Baseline to Week 48 | 0 uIU/ml |
Secondary
Change in Fasting LDL Cholesterol From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing fasting LDL cholesterol.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Fasting LDL Cholesterol From Baseline to Week 48 | -12 mg/dl |
| Arm B: No Study Drug | Change in Fasting LDL Cholesterol From Baseline to Week 48 | -7.4 mg/dl |
Secondary
Change in Fasting Total Cholesterol From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing fasting total cholesterol.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Fasting Total Cholesterol From Baseline to Week 48 | -8 mg/dl |
| Arm B: No Study Drug | Change in Fasting Total Cholesterol From Baseline to Week 48 | -2 mg/dl |
Secondary
Change in Fasting Triglycerides From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing fasting triglycerides.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Fasting Triglycerides From Baseline to Week 48 | 7 mg/dl |
| Arm B: No Study Drug | Change in Fasting Triglycerides From Baseline to Week 48 | -16 mg/dl |
Secondary
Change in HOMA-IR From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing HOMA-IR.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in HOMA-IR From Baseline to Week 48 | 0.76 (mg/dl)x(uIU/ml)/405 |
| Arm B: No Study Drug | Change in HOMA-IR From Baseline to Week 48 | -0.04 (mg/dl)x(uIU/ml)/405 |
Secondary
Change in Hyaluronic Acid From Baseline to Week 24
Absolute change was calculated as the value at week 24 minus the value at baseline.
Time frame: baseline and week 24
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing hyaluronic acid.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Hyaluronic Acid From Baseline to Week 24 | -1.62 ng/ml |
| Arm B: No Study Drug | Change in Hyaluronic Acid From Baseline to Week 24 | 3.71 ng/ml |
Secondary
Change in Hyaluronic Acid From Baseline to Week 4
Absolute change was calculated as the value at week 4 minus the value at baseline.
Time frame: baseline and week 4
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing hyaluronic acid.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Hyaluronic Acid From Baseline to Week 4 | -0.03 ng/ml |
| Arm B: No Study Drug | Change in Hyaluronic Acid From Baseline to Week 4 | 3.14 ng/ml |
Secondary
Change in Hyaluronic Acid From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing hyaluronic acid.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Hyaluronic Acid From Baseline to Week 48 | -2.74 ng/ml |
| Arm B: No Study Drug | Change in Hyaluronic Acid From Baseline to Week 48 | -1.79 ng/ml |
Secondary
Change in IL-6 From Baseline to Week 24
Absolute change was calculated as the value at week 24 minus the value at baseline.
Time frame: baseline and week 24
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing IL-6.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in IL-6 From Baseline to Week 24 | -0.53 pg/ml |
| Arm B: No Study Drug | Change in IL-6 From Baseline to Week 24 | 0.04 pg/ml |
Secondary
Change in IL-6 From Baseline to Week 4
Absolute change was calculated as the value at week 4 minus the value at baseline.
Time frame: baseline and week 4
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing IL-6.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in IL-6 From Baseline to Week 4 | -0.50 pg/ml |
| Arm B: No Study Drug | Change in IL-6 From Baseline to Week 4 | -0.01 pg/ml |
Secondary
Change in IL-6 From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing IL-6.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in IL-6 From Baseline to Week 48 | -0.46 pg/ml |
| Arm B: No Study Drug | Change in IL-6 From Baseline to Week 48 | -0.03 pg/ml |
Secondary
Change in IL-7 From Baseline to Week 24
Absolute change was calculated as the value at week 24 minus the value at baseline.
Time frame: baseline and week 24
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing IL-7.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in IL-7 From Baseline to Week 24 | 0.51 pg/ml |
| Arm B: No Study Drug | Change in IL-7 From Baseline to Week 24 | -1.36 pg/ml |
Secondary
Change in IL-7 From Baseline to Week 4
Absolute change was calculated as the value at week 4 minus the value at baseline.
Time frame: baseline and week 4
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing IL-7.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in IL-7 From Baseline to Week 4 | 0.48 pg/ml |
| Arm B: No Study Drug | Change in IL-7 From Baseline to Week 4 | -0.32 pg/ml |
Secondary
Change in IL-7 From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing IL-7.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in IL-7 From Baseline to Week 48 | 0.06 pg/ml |
| Arm B: No Study Drug | Change in IL-7 From Baseline to Week 48 | 0.53 pg/ml |
Secondary
Change in Percent Collagen VI Deposition on Subcutaneous Abdominal Adipose Tissue Pathology From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing adipose collagen VI deposition.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Percent Collagen VI Deposition on Subcutaneous Abdominal Adipose Tissue Pathology From Baseline to Week 48 | -0.41 percent area stain positive |
| Arm B: No Study Drug | Change in Percent Collagen VI Deposition on Subcutaneous Abdominal Adipose Tissue Pathology From Baseline to Week 48 | -1.36 percent area stain positive |
Secondary
Change in Percent Fibronectin Deposition on Lymph Node Pathology From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing lymphoid tissue fibronectin deposition.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Percent Fibronectin Deposition on Lymph Node Pathology From Baseline to Week 48 | 0.01 percent area stain positive |
| Arm B: No Study Drug | Change in Percent Fibronectin Deposition on Lymph Node Pathology From Baseline to Week 48 | 0.61 percent area stain positive |
Secondary
Change in Percent Fibronectin Deposition on Subcutaneous Abdominal Adipose Tissue Pathology From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing adipose tissue fibronectin deposition.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Percent Fibronectin Deposition on Subcutaneous Abdominal Adipose Tissue Pathology From Baseline to Week 48 | -0.82 percent area stain positive |
| Arm B: No Study Drug | Change in Percent Fibronectin Deposition on Subcutaneous Abdominal Adipose Tissue Pathology From Baseline to Week 48 | -4.01 percent area stain positive |
Secondary
Change in sCD14 From Baseline to Week 24
Absolute change was calculated as the value at week 24 minus the value at baseline.
Time frame: baseline and week 24
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing sCD14.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in sCD14 From Baseline to Week 24 | 0.06 mcg/ml |
| Arm B: No Study Drug | Change in sCD14 From Baseline to Week 24 | -0.08 mcg/ml |
Secondary
Change in sCD14 From Baseline to Week 4
Absolute change was calculated as the value at week 4 minus the value at baseline.
Time frame: baseline and week 4
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing sCD14.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in sCD14 From Baseline to Week 4 | -0.03 mcg/ml |
| Arm B: No Study Drug | Change in sCD14 From Baseline to Week 4 | 0.05 mcg/ml |
Secondary
Change in sCD14 From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing sCD14.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in sCD14 From Baseline to Week 48 | -0.08 mcg/ml |
| Arm B: No Study Drug | Change in sCD14 From Baseline to Week 48 | 0 mcg/ml |
Secondary
Change in sCD163 From Baseline to Week 24
Absolute change was calculated as the value at week 24 minus the value at baseline.
Time frame: baseline and week 24
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing sCD163.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in sCD163 From Baseline to Week 24 | 58.72 ng/ml |
| Arm B: No Study Drug | Change in sCD163 From Baseline to Week 24 | 9.58 ng/ml |
Secondary
Change in sCD163 From Baseline to Week 4
Absolute change was calculated as the value at week 4 minus the value at baseline.
Time frame: baseline and week 4
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing sCD163.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in sCD163 From Baseline to Week 4 | 34.08 ng/ml |
| Arm B: No Study Drug | Change in sCD163 From Baseline to Week 4 | 0.88 ng/ml |
Secondary
Change in sCD163 From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing sCD163.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in sCD163 From Baseline to Week 48 | 31.14 ng/ml |
| Arm B: No Study Drug | Change in sCD163 From Baseline to Week 48 | 5.32 ng/ml |
Secondary
Change in TGF-β1 From Baseline to Week 24
Absolute change was calculated as the value at week 24 minus the value at baseline.
Time frame: baseline and week 24
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing TGF-β1.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in TGF-β1 From Baseline to Week 24 | 175.02 pg/ml |
| Arm B: No Study Drug | Change in TGF-β1 From Baseline to Week 24 | 678.43 pg/ml |
Secondary
Change in TGF-β1 From Baseline to Week 4
Absolute change was calculated as the value at week 4 minus the value at baseline.
Time frame: baseline and week 4
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing TGF-β1.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in TGF-β1 From Baseline to Week 4 | 793.37 pg/ml |
| Arm B: No Study Drug | Change in TGF-β1 From Baseline to Week 4 | -1074.87 pg/ml |
Secondary
Change in TGF-β1 From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing TGF-β1.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in TGF-β1 From Baseline to Week 48 | -319.17 pg/ml |
| Arm B: No Study Drug | Change in TGF-β1 From Baseline to Week 48 | -516.45 pg/ml |
Secondary
Change in TGF-β2 From Baseline to Week 24
Absolute change was calculated as the value at week 24 minus the value at baseline.
Time frame: baseline and week 24
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing TGF-β2.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in TGF-β2 From Baseline to Week 24 | 75.84 pg/ml |
| Arm B: No Study Drug | Change in TGF-β2 From Baseline to Week 24 | -134.68 pg/ml |
Secondary
Change in TGF-β2 From Baseline to Week 4
Absolute change was calculated as the value at week 4 minus the value at baseline.
Time frame: baseline and week 4
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing TGF-β2.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in TGF-β2 From Baseline to Week 4 | 70.74 pg/ml |
| Arm B: No Study Drug | Change in TGF-β2 From Baseline to Week 4 | -129.40 pg/ml |
Secondary
Change in TGF-β2 From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing TGF-β2.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in TGF-β2 From Baseline to Week 48 | 44.45 pg/ml |
| Arm B: No Study Drug | Change in TGF-β2 From Baseline to Week 48 | -55.94 pg/ml |
Secondary
Change in TGF-β3 From Baseline to Week 24
Absolute change was calculated as the value at week 24 minus the value at baseline.
Time frame: baseline and week 24
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing TGF-β3.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in TGF-β3 From Baseline to Week 24 | 34.64 pg/ml |
| Arm B: No Study Drug | Change in TGF-β3 From Baseline to Week 24 | -68.01 pg/ml |
Secondary
Change in TGF-β3 From Baseline to Week 4
Absolute change was calculated as the value at week 4 minus the value at baseline.
Time frame: baseline and week 4
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing TGF-β3.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in TGF-β3 From Baseline to Week 4 | 31.26 pg/ml |
| Arm B: No Study Drug | Change in TGF-β3 From Baseline to Week 4 | -95.17 pg/ml |
Secondary
Change in TGF-β3 From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing TGF-β3.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in TGF-β3 From Baseline to Week 48 | -0.47 pg/ml |
| Arm B: No Study Drug | Change in TGF-β3 From Baseline to Week 48 | -55.21 pg/ml |
Secondary
Change in Waist Circumference From Baseline to Week 24
Absolute change was calculated as the value at week 24 minus the value at baseline.
Time frame: baseline and week 24
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing waist circumference.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Waist Circumference From Baseline to Week 24 | 0.90 cm |
| Arm B: No Study Drug | Change in Waist Circumference From Baseline to Week 24 | 0.57 cm |
Secondary
Change in Waist Circumference From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing waist circumference.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Waist Circumference From Baseline to Week 48 | 0.77 cm |
| Arm B: No Study Drug | Change in Waist Circumference From Baseline to Week 48 | -0.08 cm |
Secondary
Change in Waist-to-hip Ratio From Baseline to Week 24
Absolute change was calculated as the value at week 24 minus the value at baseline.
Time frame: baseline and week 24
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing waist-to-hip ratio.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Waist-to-hip Ratio From Baseline to Week 24 | 0 waist cm : hip cm |
| Arm B: No Study Drug | Change in Waist-to-hip Ratio From Baseline to Week 24 | 0.01 waist cm : hip cm |
Secondary
Change in Waist-to-hip Ratio From Baseline to Week 48
Absolute change was calculated as the value at week 48 minus the value at baseline.
Time frame: baseline and week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing waist-to-hip ratio.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A: Telmisartan | Change in Waist-to-hip Ratio From Baseline to Week 48 | 0 waist cm : hip cm |
| Arm B: No Study Drug | Change in Waist-to-hip Ratio From Baseline to Week 48 | 0.02 waist cm : hip cm |
Secondary
Highest Grade Non-biopsy-related Adverse Event
Safety was summarized as the highest grade non-biopsy-related sign/symptom, laboratory event, or diagnosis per participant. Grading (Grade 0: normal, Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life-threatening) was done by site clinicians using DAIDS AE Grading table. NOTE: As adipose tissue and lymph node biopsies are generally considered to be minimal risk procedures, biopsy safety profile were not formally be evaluated as an endpoint in this protocol.
Time frame: after baseline to week 48
Population: All Step 2 participants
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arm A: Telmisartan | Highest Grade Non-biopsy-related Adverse Event | Grade 1 | 0 Participants |
| Arm A: Telmisartan | Highest Grade Non-biopsy-related Adverse Event | Grade 3 | 5 Participants |
| Arm A: Telmisartan | Highest Grade Non-biopsy-related Adverse Event | Grade 2 | 11 Participants |
| Arm A: Telmisartan | Highest Grade Non-biopsy-related Adverse Event | Grade 4 | 1 Participants |
| Arm A: Telmisartan | Highest Grade Non-biopsy-related Adverse Event | Grade 0 | 12 Participants |
| Arm B: No Study Drug | Highest Grade Non-biopsy-related Adverse Event | Grade 4 | 1 Participants |
| Arm B: No Study Drug | Highest Grade Non-biopsy-related Adverse Event | Grade 0 | 6 Participants |
| Arm B: No Study Drug | Highest Grade Non-biopsy-related Adverse Event | Grade 1 | 0 Participants |
| Arm B: No Study Drug | Highest Grade Non-biopsy-related Adverse Event | Grade 2 | 3 Participants |
| Arm B: No Study Drug | Highest Grade Non-biopsy-related Adverse Event | Grade 3 | 5 Participants |
Secondary
Presence of Metabolic Syndrome at Week 48.
Components of the metabolic syndrome were defined according to the 2004 updated National Cholesterol Education Program Adult Treatment Panel III \[NCEP ATP III\] criteria) as the presence of any 3 of the following: Waist: \>40 (101.6 cm) in men, \>35 (88.9 cm) in women with the exception of Asian-Americans: \>35 (88.9 cm) in men, 31 (78.7 cm) in women; Fasting HDL-C \<40 mg/dL in men, \<50 mg/dL in women; Fasting TG ≥150 mg/dL; Diastolic blood pressure ≥85 mmHg or systolic blood pressure ≥130 mmHg; Fasting plasma glucose ≥100 mg/dL.
Time frame: Week 48
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing metabolic syndrome components.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arm A: Telmisartan | Presence of Metabolic Syndrome at Week 48. | Metabolic syndrome | 7 Participants |
| Arm A: Telmisartan | Presence of Metabolic Syndrome at Week 48. | No metabolic syndrome | 14 Participants |
| Arm B: No Study Drug | Presence of Metabolic Syndrome at Week 48. | Metabolic syndrome | 0 Participants |
| Arm B: No Study Drug | Presence of Metabolic Syndrome at Week 48. | No metabolic syndrome | 13 Participants |
Secondary
Prevalence of Metabolic Syndrome at Week 24.
Components of the metabolic syndrome will be defined according to the 2004 updated National Cholesterol Education Program Adult Treatment Panel III \[NCEP ATP III\] criteria) as the presence of any 3 of the following: Waist: \>40 (101.6 cm) in men, \>35 (88.9 cm) in women with the exception of Asian-Americans: \>35 (88.9 cm) in men, 31 (78.7 cm) in women; Fasting HDL-C \<40 mg/dL in men, \<50 mg/dL in women; Fasting TG ≥150 mg/dL; Diastolic blood pressure ≥85 mmHg or systolic blood pressure ≥130 mmHg; Fasting plasma glucose ≥100 mg/dL. NOTE: This definition of metabolic syndrome may be subject to change in accordance with current guidelines at the time of the final analysis. It will be defined in the Final Statistical Analysis Plan prior to data review for final analysis.
Time frame: Week 24
Population: Per-protocol population: Participants who 1) completed the protocol, 2) completed treatment (if on telmisartan arm), 3) did not have confirmed virologic failure, 4) had paired biopsies at baseline and week 48.~Additionally, have non-missing metabolic syndrome components.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arm A: Telmisartan | Prevalence of Metabolic Syndrome at Week 24. | Metabolic syndrome | 6 Participants |
| Arm A: Telmisartan | Prevalence of Metabolic Syndrome at Week 24. | No metabolic syndrome | 15 Participants |
| Arm B: No Study Drug | Prevalence of Metabolic Syndrome at Week 24. | Metabolic syndrome | 1 Participants |
| Arm B: No Study Drug | Prevalence of Metabolic Syndrome at Week 24. | No metabolic syndrome | 10 Participants |